About the Study: In this cohort study across inpatient and outpatient settings, HRSN screening had a substantial reach largely free of selection. Nearly 30% of screened patients demonstrated needs, with higher rates among patients who were members of racial and ethnic minority groups and publicly insured. This study provides support for inpatient HRSN screening workflows, even as policy mandates evolve, to preserve equitable reach for patient groups with disproportionately high social needs.

About the Study: In this nationwide cohort study of KD in Japan, KD incidence rebounded after the relaxation of COVID-19 pandemic-related restrictions, with age-dependent patterns. Nonpharmaceutical interventions (eg, mask-wearing) during the pandemic may explain the greater rebound pattern observed in older children; however, the minimal changes in infants suggest different exposure pathways to potential KD triggers. These findings support an age-stratified approach to KD pathogenesis research, distinguishing infants from older children.

Four privately owned animals have died from the illness.

The study, published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association, followed 756 participants over an 11-year period and examined whether reduced cardiac function could lead to adverse brain health outcomes even in the absence of cardiovascular disease. The research used data from the Vanderbilt Memory and Aging Project (VMAP), a unique longitudinal cohort designed to investigate vascular contributions to brain aging.

A protein that can dial down oxidative stress in cells helps some cancers resist treatment with a widely used class of drugs called BTK inhibitors, according to a study led by investigators at Weill Cornell Medicine. The discovery points to a possible solution to the problem of BTK inhibitor treatment resistance.

For 15 years in a row, Ochsner Health hospitals rank as the best in Louisiana for overall care; numerous specialties and procedures ranked High Performing by U.S. News & World Report.

CAMBRIDGE, Mass. — Aug 4, 2026 — Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced the publication of a collaborative study in the journal npj Precision Oncology. The peer-reviewed paper demonstrates how advanced artificial intelligence combined with comprehensive multi-omic analysis can successfully identify promising therapeutic targets in one of the rarest and least understood forms of head and neck cancer.